Pharmaxis Ltd (ASX:PXS) Insider Gary Phillips Acquires 1,640,450 Shares
Pharmaxis Ltd (ASX:PXS) Insider Gary Phillips Acquires 1,640,450 Shares
Pharmaxis Ltd (ASX:PXS – Get Rating) insider Gary Phillips acquired 1,640,450 shares of the firm's stock in a transaction dated Tuesday, November 1st. The stock was bought at an average cost of A$0.06 ($0.04) per share, with a total value of A$103,348.35 ($67,109.32).
PharMaxis有限公司(ASX：PXS-GET Rating)內部人士加里·菲利普斯在11月1日星期二的交易中收購了該公司1,640,450股股票。這隻股票的平均價格為每股0.06澳元(合0.04美元)，總價值為103,348.35澳元(合67,109.32美元)。
Gary Phillips also recently made the following trade(s):
加里·菲利普斯最近還進行了以下交易：
- On Monday, August 22nd, Gary Phillips 1,305,700 shares of Pharmaxis stock.
- 8月22日，星期一，加里·菲利普斯購買了1,305,700股Pharmax is股票。
Pharmaxis Stock Performance
PharMaxis股票表現
The company has a debt-to-equity ratio of 39.71, a quick ratio of 2.72 and a current ratio of 3.15.
該公司的負債權益比率為39.71，速動比率為2.72，流動比率為3.15。
About Pharmaxis
關於PharMaxis
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma.
PharMaxis有限公司致力於世界各地治療纖維化和炎症性疾病的保健產品的研究、開發和商業化。該公司通過甘露醇呼吸業務和新藥開發兩個部門運營。它提供Bronitol，一種用於治療囊性纖維化的吸入乾粉；以及Aridol，一種呼吸道炎症測試，用於識別抽搐或高反應性呼吸道，以及幫助診斷和管理哮喘。
Further Reading
進一步閲讀
- New Revenue Strategy, Strong Earnings, Apple Remains a Buy
- Are Investors Bailing on Travel America as Diesel Shortages Loom?
- Devon Energy Lower After Beating Q3 Views But Slashing Dividend
- Chesapeake Energy Focus on Natural Gas Leads to Strong Results
- Sell-Side Interest Drives Mondelez Higher
- 新的收入戰略，強勁的收益，蘋果仍然是一個買入者
- 柴油短缺迫在眉睫，投資者是否放棄了美國之旅？
- Devon Energy股價下跌，此前第三季度業績好於預期，但大幅削減股息
- 切薩皮克能源專注於天然氣帶來強勁業績
- 賣方興趣推動Mondelez走高
Receive News & Ratings for Pharmaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmaxis and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pharaxis Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對PharMaxis和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。